Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2020-03-23 Regulatory Filings
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Cyclopharm Company Update 2 pages 231.3KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Cyclopharm Limited dated 24 March 2020, addressed to the Australian Securities Exchange. It provides updates on several topics: the impact of COVID-19 on the use of their product Technegas, readiness to submit a New Drug Application (NDA) to the US FDA, a recent capital raising completed in December 2019, and ongoing litigation updates including a Statement of Claim lodged with the NSW Supreme Court. The document is relatively short (6789 characters) and structured as a company announcement rather than a detailed financial report or regulatory filing. It does not contain detailed financial statements, comprehensive management discussion, or full audit information. Instead, it provides a corporate update on business activities, regulatory submission status, capital raising summary, and legal proceedings. This fits best with the category of Regulatory Filings (RNS), which is a general category for regulatory announcements and miscellaneous filings that do not fit other specific categories. It is not an Annual Report, Interim Report, Earnings Release, or Capital/Financing Update in the strict sense, as it does not present detailed financial results or capital structure changes but rather a broad company update including litigation and regulatory submission status. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-03-23 English
Change of Director's Interest Notice 2 pages 205.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of shares acquired, disposed, and held before and after the change. The document is a formal notification of a director's personal share transactions. It does not contain financial statements, management discussion, or other report content. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3271 characters, consistent with a short notice rather than a full report. Therefore, the correct classification is DIRS.
2020-03-16 English
Change of Director's Interest Notice 2 pages 215.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a change in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the interest, and the date of change. This matches the description of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document is specific to a director's share transactions and does not contain financial statements or broader company information, so it is not an Annual Report or Earnings Release. Therefore, the correct classification is Director's Dealing (DIRS).
2020-03-16 English
Change of Director's Interest Notice 2 pages 205.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of securities held before and after the change, the nature of the transaction (on-market trade), and dates. There is no financial performance data, earnings information, or report content. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 3270 characters, which is consistent with a detailed insider trading notice rather than a full financial report or announcement. Therefore, the correct classification is DIRS.
2020-03-12 English
Cyclopharm Investor Presentation 46 pages 3.0MB
Investor Presentation Classification · 95% confidence The document is titled 'Financial Year 2019 Results Presentation' and dated 3 March 2020. It contains detailed financial data including sales revenue, gross margin, profit before tax, balance sheet figures, and operational highlights for the fiscal year ended 31 December 2019. The content includes strategic priorities, company overview, and detailed financial performance metrics, which are typical of an investor presentation. The document is a presentation format rather than a formal annual report (10-K) or interim report (IR). It is not a brief factsheet or a simple earnings release but a comprehensive presentation aimed at investors, covering financials, strategy, and market position. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed financial data support this classification with high confidence.
2020-03-02 English
Change of Director's Interest Notice 2 pages 205.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of securities held before and after the change, the nature of the transaction (on-market trade), and dates. This is a clear report of personal share transactions by a company director. The document length is 3272 characters, which is typical for such notices. There is no indication that this is a full financial report or an announcement of a report. Therefore, the document fits the definition of Director's Dealing (DIRS).
2020-03-01 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.